Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Houston Medicaid Fraud Lawyer J. Mark Brewer Comments On $27 Million Settlement To Resolve Allegations Of Medicaid Fraud
  • USA - English


News provided by

Big Voodoo Interactive

Mar 30, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Houston, TX (PRWEB) March 30, 2014 -- Teva Pharmaceutical Industries Ltd. recently agreed to pay the federal government and the State of Illinois $27.6 million to resolve allegations of illegally paying a doctor to prescribe certain dangerous drugs, according to Bloomberg News. Houston Medicaid fraud lawyer J. Mark Brewer of Brewer & Pritchard, P.C. said he hopes the settlement sends a clear message to other corporations that such alleged behavior will not be tolerated.

These corporations cannot play games with people’s lives simply to make a profit. They need to make responsible decisions and not put pressure on doctors to prescribe drugs that could potentially harm people.

Post this

Attorney Brewer based his comments on an article published March 11, 2014, by Bloomberg News about $27.6 million payment to settle the case.

“Drug companies need to realize that there are consequences for their actions,” Brewer said. “These corporations cannot play games with people’s lives simply to make a profit. They need to make responsible decisions and not put pressure on doctors to prescribe drugs that could potentially harm people. Patients trust doctors to prescribe drugs that will help them get better. When doctors and drug companies violate that trust, these companies and reckless doctors need to be punished. People’s lives are literally on the line.”

The U.S. Justice Department ruled that certain units of Teva Pharmaceutical Industries Ltd. violated the U.S. False Claims Act by paying a doctor in Illinois $50,000 to prescribe a generic form of clozapine to Medicare and Medicaid patients, according to the Bloomberg News article.

Clozapine is used to treat schizophrenia and has, “serious side effects and is considered a drug of last resort, especially for elderly patients,” according to a statement from the U.S. Justice Department quoted in the Bloomberg News article.

Israel-based Teva Pharmaceutical Industries Ltd. is the largest generic drug manufacturer in the world, Bloomberg News reported. As part of the $27.6 million settlement, Teva Pharmaceutical Industries Ltd. agreed to pay the State of Illinois $15.5 million and the federal government $12.1 million, Bloomberg News reported.

The False Claims Act was created to expose government fraud and reward whistleblowers who speak out against government corruption. This 1863 federal law rewards people who report government fraud and other criminal activity, according to Houston False Claims Act attorney J. Mark Brewer of Brewer & Pritchard, P.C.

“Our tax dollars should not be wasted on fraudulent schemes that could potentially cause serious harm to innocent people,” Brewer said. “Laws like the False Claims Act exists for a reason: to root out corruption and fraud. The settlement involving Teva Pharmaceutical Industries Ltd. shows that this law remains as relevant as ever 151 years after it was created. Our law firm knows firsthand the effectiveness of the False Claims Act. That’s because we handled many significant Medicaid fraud cases in Texas. These cases can be very complicated and extremely difficult to prove. That’s why we strongly encourage people who suspect this form of fraud to contact us as soon as possible.”

The Bloomberg News article cited is “Teva to Pay $27.6 Million to Settle Clozapine Payoff Case.”

The case is U.S. v. Reinstein, 12-09167, U.S. District Court, Northern District of Illinois (Chicago).

About Brewer & Pritchard, P.C.

Serving clients throughout Texas and across the country, the attorneys at Brewer & Pritchard, P.C. have a well-earned reputation for being knowledgeable, experienced lawyers focused on results. The Houston law firm handles a wide variety of cases, including Medicaid fraud, whistleblower claims, business law, corporate law, mergers, acquisitions and other legal issues. The law firm discreetly investigates every case and respects clients’ privacy. For more information about what to do if you suspect Medicaid fraud and the legal options available to Medicaid fraud whistleblowers, call 800-445-8710 or complete the online contact form.

Not certified by the Texas Board of Legal Specialization.

Brewer & Pritchard, P.C.
Three Riverway, 18th Floor
Houston, Texas 77056
800-445-8710
http://www.bplaw.com

Jacob M Del Hagen, Big Voodoo Interactive, http://www.bigvoodoo.com, +1 (413) 650-0593, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.